An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Sponsor: TG Therapeutics, Inc.
This PHASE3 trial investigates Relapsing Multiple Sclerosis (RMS) and is currently ongoing. TG Therapeutics, Inc. leads this study, which shows 68 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
68 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 63 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2024 — Apr 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Enrolling By Invitation PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Enrolling By Invitation PHASE3
-
May 2023 — Jul 2023 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2023 — May 2023 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Enrolling By Invitation PHASE3
-
May 2022 — Jun 2022 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2022 — May 2022 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE3
-
May 2021 — Jun 2021 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Enrolling By Invitation PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Enrolling By Invitation PHASE3
-
May 2020 — Jun 2020 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2020 — May 2020 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TG Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Amherst, United States , Arkhangelsk, Russia , Barnaul, Russia , Belgrade, Serbia , Bryansk, Russia , Chelyabinsk, Russia , Cherkasy, Ukraine , Chernihiv, Ukraine , Chernivtsi, Ukraine and 56 more locations